Profound Medical Corp: ExeGi Pharma's Breakthrough Treatment for J-Pouch Patients Shows Promise

ExeGi Pharma's Breakthrough in Treating J-Pouch Patients: A New Hope for Ulcerative Colitis Survivors

ExeGi Pharma LLC recently announces promising outcomes from the Phase 1b segment of its PROF study, which investigates the safety and efficacy of EXE-346, a live biotherapeutic drug, specifically designed for patients with ileal pouch-anal anastomosis (IPAA), colloquially known as "J-pouch" patients. This demographic primarily includes individuals who have undergone surgery as a treatment for ulcerative colitis and often face complications such as excessive stool frequency. The study's results indicate a significant reduction in bowel movement frequency by 18%, with the average daily movements decreasing from 13.09 to 10.69. Additionally, nighttime awakenings are reduced by 28%, dropping from an average of 2.39 to 1.73 times per night after four weeks of treatment with a daily dosage of 3,000 billion live probiotics.

The findings of the PROF study are particularly noteworthy as they not only highlight the potential effectiveness of EXE-346 in alleviating a common postoperative issue but also emphasize the safety profile of the treatment, with no serious adverse events reported during the trial. Dr. Hans Herfarth, director at the University of North Carolina Multidisciplinary IBD Center, expresses optimism regarding these early results, suggesting that they may lead to enhanced quality of life for J-pouch patients who often struggle with debilitating gastrointestinal symptoms. The positive feedback from clinical experts underscores the significance of continued exploration into the therapeutic benefits of live biotherapeutics like EXE-346.

Looking ahead, ExeGi Pharma plans to advance the research with a Phase 2 placebo-controlled study scheduled to commence in January 2025 across eight clinical sites in the U.S. This next phase will further investigate the drug's effectiveness and solidify its potential role in the management of symptoms related to IPAA. ExeGi Pharma’s commitment to developing scientifically supported live biotherapeutic and probiotic medicines aligns with its mission to address critical health needs while also adhering to environmentally sustainable practices.

In summary, the encouraging results from ExeGi Pharma’s PROF study mark a significant step forward in the treatment options available for J-pouch patients, who have long faced challenges following ulcerative colitis surgery. The ongoing research reflects a promising future for individuals seeking relief from their symptoms through innovative therapeutic approaches. More details regarding the PROF study can be accessed via clinicaltrials.gov under the identifier NCT05938465.